Accordingly, the individual response to immune checkpoint inhibitor (ICI) therapy is largely dependent on the DNAM-1 expression levels in cytotoxic lymphocytes [28,89,130], highlighting a key role for DNAM-1 in the regulation of cytotoxic lymphocyte tumor immune surveillance. Here, CD226 is linked to neoplasm.